Analogues of 2'-hydroxychalcone with modified C4-substituents as the inhibitors against human acetylcholinesterase.

A series of C4-substituted tertiary nitrogen-bearing 2'-hydroxychalcones were designed and synthesised based on a previous mixed type acetylcholinesterase inhibitor. Majority of the 2'-hydroxychalcone analogues displayed a better inhibition against acetylcholinesterase (AChE) than butyrylcholinesterase (BuChE). Among them, compound 4c was identified as the most potent AChE inhibitor (IC50: 3.3 µM) and showed the highest selectivity for AChE over BuChE (ratio >30:1). Molecular docking studies suggested that compound 4c interacts with both the peripheral anionic site (PAS) and catalytic anionic site (CAS) regions of AChE. ADMET analysis confirmed the therapeutic potential of compound 4c based on its blood-brain barrier penetrating. Overall, the results suggest that this 2'-hydroxychalcone deserves further investigation into the therapeutic lead for Alzheimer's disease (AD).

In vitro functional evaluation of isolaureline, dicentrine and glaucine enantiomers at 5-HT2 and α1 receptors.

Compounds with activity at serotonin (5-hydroxytryptamine) 5-HT2 and α1 adrenergic receptors have potential for the treatment of central nervous system disorders, drug addiction or overdose. Isolaureline, dicentrine and glaucine enantiomers were synthesized, and their in vitro functional activities at human 5-HT2 and adrenergic α1 receptor subtypes were evaluated. The enantiomers of isolaureline and dicentrine acted as antagonists at 5-HT2 and α1 receptors with (R)-isolaureline showing the greatest potency (pKb  = 8.14 at the 5-HT2C receptor). Both (R)- and (S)-glaucine also antagonized α1 receptors, but they behaved very differently to the other compounds at 5-HT2 receptors: (S)-glaucine acted as a partial agonist at all three 5-HT2 receptor subtypes, whereas (R)-glaucine appeared to act as a positive allosteric modulator at the 5-HT2A receptor.

Bis(µ-hexa-deca-noato-κO:O)bis-[(2,2'-bipyridine-κN,N')(hexa-deca-noato-κO)copper(II)] methanol disolvate.

The asymmetric unit of the title compound, [Cu(2)(C(16)H(31)O(2))(4)(C(10)H(8)N(2))(2)]·2CH(3)OH, contains one half-mol-ecule of the metal complex solvated by a methanol mol-ecule. In the complex, two of the metal atoms are doubly bridged by two monodentate bridging hexa-deca-noate ligands around a center of inversion. The square-pyramidal geometry around each Cu(II) ion is completed by a terminal hexa-deca-noate O atom and two N atoms from a 2,2'-bipyridine ligand. The alkyl chains of the carboxyl-ate ligands are arranged in a parallel manner with an all-trans conformation. In the crystal, a π-π inter-action formed by the bipyridine rings [centroid-centroid separation = 3.7723 (17) Å] and inter-molecular C-H⋯O hydrogen bonds link the complex mol-ecules into infinite chains along the b axis. An O-H⋯O interaction between the methanol solvate and one of the carboxylate O atoms is also observed.

4,4',6,6'-Tetra-tert-butyl-2,2'-[butane-1,4-diylbis(nitrilo-methanylyl-idene)]diphenol.

The title compound, C(34)H(52)N(2)O(2), is centrosymmetric, the mid-point of the central C-C bond being located on an inversion centre. Intra-molecular O-H⋯N and weak C-H⋯O hydrogen bonds are observed, but no significant inter-molecular inter-actions occur in the crystal structure.

2,2'-[Nonane-1,9-diylbis(nitrilo-methyl-idyne)]diphenol.

In the title Schiff base compound, C(23)H(30)N(2)O(2), the complete mol-ecule is generated by crystallographic twofold symmetry, with one C atom lying on the rotation axis. The nonane chain adopts a linear conformation and the hydr-oxy group forms an intra-molecular O-H⋯N hydrogen bond to the imine group.